CRISPR Therapeutics
Latest round
- Series B
Last raised
- Jun 2016
Total raised
- $127M
Investors
- 9
About CRISPR Therapeutics
CRISPR Therapeutics AG, based in Switzerland, is a leading biotechnology firm specializing in transformative gene-based medicines through CRISPR technology.CRISPR Therapeutics AG focuses on developing gene-editing solutions for serious diseases.50 mn.CRISPR Therapeutics develops gene-based medicines using CRISPR technology. Its notable product, CASGEVY™ (exagamglogene autotemcel), is approved for treating sickle cell disease and transfusion-dependent beta-thalassemia.70 mn.CRISPR Therapeutics plans to expand its product offerings and market reach in the coming years.50 mn in July 2020, the company aims to accelerate the development of new therapies and explore entry into new geographic markets. It focuses on advancing its pipeline of gene-editing solutions for various diseases, with ongoing clinical programs that may lead to additional product launches in the near future.
Who invested in CRISPR Therapeutics
9 investors across 4 rounds
See all investors in CRISPR Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CRISPR Therapeutics
Who invested in CRISPR Therapeutics?
CRISPR Therapeutics has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CRISPR Therapeutics raised?
CRISPR Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did CRISPR Therapeutics last raise money?
CRISPR Therapeutics's most recent round on record is a Series B, in Jun 2016.
What does CRISPR Therapeutics do?
CRISPR Therapeutics AG, based in Switzerland, is a leading biotechnology firm specializing in transformative gene-based medicines through CRISPR technology.
Where is CRISPR Therapeutics headquartered?
CRISPR Therapeutics is headquartered in Zug, Switzerland.
Which VCs invest in companies like CRISPR Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at CRISPR Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like CRISPR Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.